Flow fluorescence technology is a clinically applied high-throughput luminescent detection technology based on encoded microspheres and flow technology. It is also known as liquid chip, suspension array, Luminex? xMAP technology, and more. As a new-generation high-throughput molecular diagnostic technology platform following biochip technology and chemiluminescence technology, it has become a major focus in the field of clinical diagnosis and life science research. This technology integrates the advantages of colored microspheres, applied fluidics, laser technology, and high-speed digital signal processing technology. Currently, it has been widely used in research fields such as immunoassays, nucleic acid detection, enzymatic analysis, and receptor-ligand recognition analysis. It possesses multiple advantages: it enables simultaneous detection of multiple indicators, offers high throughput and fast speed, requires small sample volumes, can detect both nucleic acids and proteins, and is applicable to both clinical testing and scientific research—making it the "dream technology" for every laboratory professional. Over nearly 20 years of development, flow fluorescence technology has integrated technologies including fluorescently encoded microspheres, laser detection, and signal processing. For the key qualitative and quantitative detection of nucleic acids or proteins, the signal can be amplified through labeled biotin and streptavidin-phycoerythrin (SA-PE); alternatively, direct labeling with phycoerythrin (PE) is also feasible. This truly realizes a high-tech solution characterized by automation, high-throughput testing, low cost, and high sensitivity.

At present, it has been widely adopted by major domestic clinical testing enterprises in China to establish independent reagent development platforms. It is applied in numerous fields, including HLA panels, autoimmune disease detection, allergen detection, gene mutation detection, tumor marker detection, and HPV genotyping.

Crystal Biology is capable of extracting and purifying phycobiliproteins at the reagent grade. These phycobiliproteins feature a fluorescence ratio and purity higher than the industry average. Additionally, the company provides streptavidin-labeled phycoerythrin (SA-PE) products with strong fluorescent signals, high signal-to-noise ratio, and low non-specificity. It stably supplies such products and related services to world-renowned biotechnology companies and clinical diagnostic companies.